Christina L. Fanola

TL;DR: In a high‐risk population of overweight or obese patients, lorcaserin facilitated sustained weight loss without a higher rate of major cardiovascular events than that with placebo.

TL;DR: This consensus practice document provides a comprehensive review of the diagnosis, treatment, and follow-up of acute PE, including both clinical data and consensus opinion to provide guidance for clinicians caring for these patients.

TL;DR: The "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease" as discussed by the authors provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance of patients with aortic disease across its multiple clinical presentation subsets (i.e., asymptomatic, stable symptomatic, and acute aortric syndromes).

TL;DR: In patients with atrial fibrillation who develop malignancy, the efficacy and safety profile of edoxaban relative to warfarin is preserved, and it may represent a more practical alternative.

TL;DR: In patients after ACS, IL‐6 concentration is associated with adverse cardiovascular outcomes independent of established risk predictors and biomarkers, lending support to the concept of IL‐ 6 as a potential therapeutic target in patients with unstable ischemic heart disease.